共 50 条
Immunogenicity and Reactogenicity of Ad26.COV2.S in Korean Adults: A Prospective Cohort Study
被引:1
|作者:
Hyun, Hakjun
[1
]
Choi, Min Joo
[4
,7
]
Heo, Jung Yeon
[5
]
Seo, Yu Bin
[6
]
Nham, Eliel
[1
]
Yoon, Jin Gu
[1
]
Seong, Hye
[1
]
Noh, Ji Yun
[1
,2
,3
]
Cheong, Hee Jin
[1
]
Kim, Woo Joo
[1
,2
,3
]
Choi, Ju-Yeon
Lee, Young Jae
Lee, Hye Won
Kim, Sung Soon
Kim, Byoungguk
Song, Joon Young
[1
,2
,3
]
机构:
[1] Korea Univ, Dept Internal Med, Div Infect Dis, Coll Med, Seoul, South Korea
[2] Korea Univ, Asia Pacific Influenza Inst, Coll Med, Seoul, South Korea
[3] Vaccine Innovat Ctr KU Med VIC K, Seoul, South Korea
[4] Catholic Kwandong Univ, Dept Internal Med, Int St Marys Hosp, Coll Med, Incheon, South Korea
[5] Ajou Univ, Dept Infect Dis, Sch Med, Suwon, South Korea
[6] Hallym Univ, Kangnam Sacred Heart Hosp, Dept Internal Med, Div Infect Dis,Coll Med, Seoul, South Korea
[7] Natl Inst Infect Dis, Ctr Vaccine Res, Div Vaccine Clin Res, Cheongju, South Korea
关键词:
SARS-CoV-2;
COVID-19;
Vaccines;
Adenovirus Vector;
Humoral Immunity;
Cellular Immunity;
Adverse Events;
D O I:
10.3346/jkms.2022.37.e210
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Background: As the coronavirus disease 2019 (COVID-19) pandemic continues, there are concerns regarding waning immunity and the emergence of viral variants. The immunogenicity of Ad26.COV2.S against wild-type (WT) and variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) needs to be evaluated. Method: This prospective cohort study was conducted between June 2021 and January 2022 at two university hospitals in South Korea. Healthy adults who were scheduled to be vaccinated with Ad26.COV2.S were enrolled in this study. The main outcomes included anti-spike (S) IgG antibody and neutralizing antibody responses, S-specific T-cell responses (interferon-. enzyme-linked immunospot assay), solicited adverse events (AEs), and serious AEs. Results: Fifty participants aged >= 19 years were included in the study. Geometric mean titers (GMTs) of anti-S IgG were 0.4 U/mL at baseline, 5.2 +/- 3.0 U/mL at 3-4 weeks, 55.7 +/- 2.4 U/mL at 5-8 weeks, and 81.3 +/- 2.5 U/mL at 10-12 weeks after vaccination. GMTs of 50% neutralizing dilution (ND50) against WT SARS- CoV-2 were 164.6 +/- 4.6 at 3-4 weeks, 313.9 +/- 3.6 at 5-8 weeks, and 124.4 +/- 2.6 at 10-12 weeks after vaccination. As for the S-specific T-cell responses, the median number of spot-forming units/106 peripheral blood mononuclear cell was 25.0 (5.0-29.2) at baseline, 60.0 (23.3-178.3) at 5-8 weeks, and 35.0 (13.3-71.7) at 10-12 weeks after vaccination. Compared to WT SARS-CoV-2, ND50 against Delta and Omicron variants was attenuated by 3.6-fold and 8.2-fold, respectively. The most frequent AE was injection site pain (82%), followed by myalgia (80%), fatigue (70%), and fever (50%). Most AEs were grade 1-2, and resolved within two days. Conclusion: Single-dose Ad26.COV2.S was safe and immunogenic. NAb titer and S-specific T-cell immunity peak at 5-8 weeks and rather decrease at 10-12 weeks after vaccination. Cross-reactive neutralizing activity against the Omicron variant was negligible.
引用
收藏
页数:9
相关论文